Results 41 to 50 of about 3,972 (210)

Interleukin‐40 in Systemic Sclerosis: A Treatment‐Sensitive Marker of Immune Modulation Rather Than Disease Activity

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Interleukin‐40 (IL‐40) is a recently identified cytokine primarily produced by activated B cells and implicated in immune regulation across several autoimmune diseases. Although B cell–driven immune dysregulation plays a central role in systemic sclerosis (SSc), the circulating behavior and clinical relevance of IL‐40 in this disease remain ...
İbrahim Vasi, Emin Ümit Bağrıaçık, Rıza Can Kardaş, Nihan Örüklü, Melek Yaman, Derya Yıldırım, Burcugül Kaya, Rahime Duran, İbrahim Karaduman, İbrahim Yahya Çakır, Hamit Küçük, Berna Göker, Abdulsamet Erden, Mehmet Akif Öztürk   +13 more
wiley   +1 more source

Evaluation of the Performance of Large Language Models in the Management of Axial Spondyloarthropathy: Analysis of EULAR 2022 Recommendations

Diagnostics
Introduction: Guidelines have great importance in revealing complex and chronic conditions such as axial spondyloarthropathy. The aim of this study is to compare the answers given by various large language models to open-ended questions created from ASAS–
Ahmet Usen, Ozlem Kuculmez
doaj   +1 more source

Differences in the course of coxitis in men and women with early axial spondyloarthritis

Научно-практическая ревматология, 2023
Introduction. Currently, there is a small number of studies devoted to the differences in the manifestations of axial spondyloarthritis (axSpA) in men and women, and there are no studies assessing the frequency of coxitis in axSpA in patients of ...
E. M. Agafonova, Sh. Erdes, T. V. Dubinina, A. B. Demina, A. V. Smirnov   +4 more
doaj   +1 more source

Integrating Behavioral Health Services for Individuals With Rheumatic Diseases: A Quantitative Analysis of a Pilot Study

ACR Open Rheumatology, Volume 8, Issue 7, July 2026.
Objective Chronic pain, depressive and anxiety symptoms are common comorbidities among persons with rheumatic disease (RD) and contribute to increased symptom burden and reduced quality of life (QoL). Behavioral health (BH) interventions to motivate behavior change and promote self‐management can effectively address these conditions.
Shannon Teaw, Jessica Link‐Malcolm, Michelle Ghebranious, Dorothy Jet Patterson, Jenny Foster, Sofia Bereket, Urooj Wahid, Puneet Bajaj, E. Blair Solow, Linda S. Hynan, Jennifer L. Barton, Una E. Makris   +11 more
wiley   +1 more source

Longitudinal Associations Between Inflammatory Biomarkers and Fatigue in Patients With Colorectal Cancer: A Multicenter Study

Cancer Medicine, Volume 15, Issue 7, July 2026.
ABSTRACT Purpose Fatigue affects up to 90% of patients with cancer during chemotherapy and persists in approximately 30% after treatment completion. This study examined the longitudinal associations between fatigue and 16 inflammatory markers in patients with colorectal cancer (CRC) up to 3 years after surgery.
Nicole C. Loroña, Louisa Liu, Elham Kazemian, Nicholas Acuna, Mary C. Playdon, Christopher L. Cubitt, Shaowli Kabir, Sylvia L. Crowder, Nathalie Nguyen, Maria Gomez, Victoria Damerell, Kathi Mooney, Patricia A. Erickson, Mmadili Ilozumba, Caroline Himbert, Erin Siegel, Cornelia M. Ulrich, Christopher I. Li, David Shibata, Adetunji T. Toriola, Jennifer Ose, Anita R. Peoples, Sheetal Hardikar, Doratha A. Byrd, Julienne E. Bower, Aasha I. Hoogland, Xiaoyin Li, Brent J. Small, Biljana Gigic, Heather S. L. Jim, Jane C. Figueiredo   +30 more
wiley   +1 more source

Comorbidities in ankylosing spondylarthritis

, 2013
Department of Internal Medicine, Medical Clinic №5. Department of Rheumatology and Nephrology. Republican Clinical Hospital, Department of Rheumatology, Chisinau, MoldovaObjective: to determine the frequency of associated pathologies in ankylosing ...
Groppa, Liliana, Rotaru, Larisa, Sarbu, Oxana   +2 more
core   +1 more source

Systemic lupus erythematosus induced by anti-tumor necrosis factor α therapy in inflammatory rheumatic diseases: a case series

Reumatismo
This case series aims to characterize the development of systemic lupus erythematosus (SLE) induced by anti-tumor necrosis factor α (anti-TNFα) therapy in patients with inflammatory rheumatic diseases, namely rheumatoid arthritis (RA), spondylarthritis (
D. Oliveira, A. Martins, F. Martins, C. Gomes, S. Pimenta, C. Vaz, L. Costa, M. Bernardes   +7 more
doaj   +1 more source

The Impact of Spondyloarthritis on Health-Related Quality of Life and Healthcare Resource Utilization in Saudi Arabia: A Narrative Review and Directions for Future Research

Open Access Rheumatology: Research and Reviews, 2023
Hanan Al Rayes,1 Hany Salah,2 Tharwat Hamad,3 Mohab Soliman,4 Mohamed Bedaiwi5 1Division of Rheumatology, Department of Internal Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia; 2Therapeutic Area Lead Rheumatology, Intercontinental ...
Al Rayes H, Salah H, Hamad T, Soliman M, Bedaiwi M   +4 more
doaj  

The place of chondroprotectors in the treatment of osteoarthritis of the spine

Медицинский совет, 2016
Osteoarthritis is the major nosological form representing degenerative joint disease, characterized by chronic, steadily progressive course. The disease is primarily caused by an imbalance between the anabolic and catabolic processes, especially in the ...
N. V. Pizova
doaj   +1 more source

Real‐World Effectiveness and Safety of Upadacitinib in Combination With Biologic Therapy in Patients With Inflammatory Bowel Disease

JCC Plus, Volume 1, Issue 3, May 2026.
ABSTRACT Background Upadacitinib is a selective Janus kinase 1 inhibitor that has demonstrated rapid onset and efficacy in patients with moderate‐to‐severe Crohn's disease (CD) and ulcerative colitis (UC). Here, we describe the real‐world efficacy and safety of upadacitinib in combination with biologic therapies for IBD.
Nicole M. Garcia, Uma Mahadevan, Sara Lewin, Rishika Chugh   +3 more
wiley   +1 more source